The use of sacubitril/valsartan has been fully recognized in the most recent European and American guidelines that recommend in class I the prescription of this drug in heart failure patients with reduced systolic function. Besides the effects on cardiovascular mortality and heart failure hospitalization, sacubitril/valsartan significantly reduces NT-proBNP levels and improves cardiac remodeling, recognized as one of the mechanistic effects of the drug that is linked to favorable prognostic effects. A careful evaluation of the patients' clinical profile is needed to implement the use of sacubitril/valsartan into clinical practice and to make the treatment successful. This second part of the position paper focuses on the mechanistic effects of angiotensin receptor-neprilysin inhibitors and on its placement in current guidelines, also suggesting the use of sacubitril/valsartan in specific clinical settings.

Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice / Filardi, P. P.; Indolfi, C.; Paolillo, S.; Agostoni, P.; Basso, C.; Barilla, F.; Correale, M.; Curcio, A.; Mancone, M.; Merlo, M.; Metra, M.; Muscoli, S.; Nodari, S.; Palazzuoli, A.; Pedrinelli, R.; Pontremoli, R.; Senni, M.; Volpe, M.; Sinagra, G.. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1972-6481. - 23:4(2022), pp. 299-308. [10.1714/3766.37540]

Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice

Filardi P. P.;Indolfi C.;Paolillo S.;Curcio A.;
2022

Abstract

The use of sacubitril/valsartan has been fully recognized in the most recent European and American guidelines that recommend in class I the prescription of this drug in heart failure patients with reduced systolic function. Besides the effects on cardiovascular mortality and heart failure hospitalization, sacubitril/valsartan significantly reduces NT-proBNP levels and improves cardiac remodeling, recognized as one of the mechanistic effects of the drug that is linked to favorable prognostic effects. A careful evaluation of the patients' clinical profile is needed to implement the use of sacubitril/valsartan into clinical practice and to make the treatment successful. This second part of the position paper focuses on the mechanistic effects of angiotensin receptor-neprilysin inhibitors and on its placement in current guidelines, also suggesting the use of sacubitril/valsartan in specific clinical settings.
2022
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice / Filardi, P. P.; Indolfi, C.; Paolillo, S.; Agostoni, P.; Basso, C.; Barilla, F.; Correale, M.; Curcio, A.; Mancone, M.; Merlo, M.; Metra, M.; Muscoli, S.; Nodari, S.; Palazzuoli, A.; Pedrinelli, R.; Pontremoli, R.; Senni, M.; Volpe, M.; Sinagra, G.. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1972-6481. - 23:4(2022), pp. 299-308. [10.1714/3766.37540]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/884770
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact